Profluent, Lilly Partner to Advance AI Gene Editing Tech
EMERYVILLE, CALIFORNIA, April 29, 2026 Profluent has announced a strategic multi-program research collaboration with Eli Lilly and Company to...
Eli Lilly
Advertisement
Eli Lilly to Acquire Ajax Therapeutics in $2.3B Oncology Deal
INDIANAPOLIS, NEW YORK & CAMBRIDGE, Mass., April 27, 2026 Eli Lilly and Company has announced a definitive agreement to...
Eli Lilly to Acquire Kelonia for In Vivo CAR-T Breakthrough
INDIANAPOLIS and BOSTON, Mass., April 20, 2026 Eli Lilly and Company has announced a landmark agreement to acquire Kelonia...
Lilly Foundayo Shows Strong Phase 3 Diabetes Results
INDIANAPOLIS, April 16, 2026 Eli Lilly and Company announced positive results from its ACHIEVE-4 Phase 3 clinical trial, demonstrating...
Eli Lilly to Acquire CrossBridge Bio for ADC Platform
Houston, Texas, U.S. | April 15, 2026 Eli Lilly and Company has announced a strategic agreement to acquire CrossBridge...
Advertisements
Eli Lilly Reports Breakthrough Phase 3 Jaypirca Results
Indianapolis, Indiana | April 13, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3...
Lilly Launches Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral...
FDA Approves Lilly Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, USA — April 1, 2026 In a landmark advancement in obesity treatment and metabolic disease management, Eli Lilly...
Lilly to Acquire Centessa in $7.8B Pharma Deal
INDIANAPOLIS, USA & BOSTON, USA & LONDON, UK, March 31, 2026 Eli Lilly and Company has announced a definitive...
Insilico, Lilly Sign $2.75B AI Drug Discovery Deal
Hong Kong | March 30, 2026 Strategic AI Collaboration to Accelerate Drug Discovery Insilico Medicine has announced a major...
Advertisement
